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Abstract Interleukin (IL)-4 and IL-13 share a wide range of 
activities. Prominent among these is the ability to antagonize 
many interferon (IFNJ-y-induced activities. Here we demonstrate 
that IL-4 and IL-13 totally abrogate IFN-y-induced nitric oxide 
(NO) production and inducible nitric oxide synthase (iNOS) 
mRNA and protein synthesis in a murine macrophage cell line. 
IFN-y-treated cells infected with herpes simplex virus type 2 
(HSV-2) or costimulated with tumor necrosis factor (TNF)-a 
showed an enhanced reactivity, which was only partially reduced 
by IL-4/13. The results indicate that IL-4 and IL-13 function by 
intervening with a step prior to iNOS transcription by 
antagonizing IFN-y-induced signal(s) without counteracting 
synergistic virus- or TNF-a-induced signals. The beneficial 
effect of a sustained NO production in foci of virus infection is 
suggested. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Nitric oxide (NO) is a gaseous molecule with properties of a 
free radical due to an unpaired electron. Consequently it is 
very reactive and can cause severe damage on substances such 
as DNA, proteins, lipids and carbohydrates [1-4]. This prob-
ably works through generation of peroxynitrite via reaction 
with 0 2 , nicely illustrating how two pathways each generat-
ing relatively deleterious compounds together become even 
more powerful. It has been found that NO is produced in 
large amounts by activated macrophages [5] and is involved 
in the antitumor [6], antimicrobial [7,8] and antiviral [9,10] 
action of these cells. 
NO is produced from arginine by the enzyme inducible 
nitric oxide synthase (iNOS). The main inducers of iNOS 
are interferon-y (IFN-y), lipopolysaccharide (LPS) and, in 
conjunction with these, tumor necrosis factor-a (TNF-a) 
[11,12]. They function by activating interferon regulatory fac-
tor 1 (IRF-1), signal transducer and activator of transcription 
1 (STAT1) and nuclear factor ( N F ) - K B which bind to sites in 
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the iNOS promoter [11,13,14]. Studies in IRF-1 knock-out 
mice and analyses of cycloheximide sensitivity have revealed 
that de novo IRF-1 synthesis is essential in iNOS transcrip-
tion [13,15,16]. 
Because NO is extremely reactive, it is potentially toxic to 
the host. Therefore, the production must be tightly regulated. 
In recent years it has become clear that many effects induced 
by the T-helper cell type 1 (Thl) cytokine IFN-y are counter-
acted by Th2 cytokines like interleukin (IL)-4 and IL-13 [17-
20]. IL-4 is primarily produced by activated Th2 cells but also 
by some other T-cell subpopulations as well as by cells of the 
basophil/mast cell lineage [21,22]. IL-13 has thus far only been 
found to be expressed by activated Th2 cells [23,24]. The two 
cytokines share a wide range of functions [20,24,25]. 
In mouse macrophages we have previously shown that in-
fection with herpes simplex virus type 2 (HSV-2) synergizes 
with IFN-y in induction of NO production and that this syn-
ergy is largely due to autocrine secretion of TNF-a [26]. To 
get a broader understanding of iNOS regulation during a 
virus infection we have analyzed putative down-regulators of 
iNOS and initiated studies on the molecular mechanisms 
underlying their actions. 
In the present study we have analyzed the ability of IL-4 
and IL-13 to antagonize IFN-y-induced NO production in the 
murine macrophage cell line J774A.1 in the presence or ab-
sence of infection with HSV-2. We have found that both IL-4 
and IL-13 completely abolish IFN-y-induced NO production 
and that HSV-2- and TNF-a-mediated signals can partly 
overcome this down-regulating effect, thus allowing some 
NO production despite the presence of high levels of IL-4 
and IL-13. The two Th2 cytokines work by diminishing 
iNOS mRNA levels and we suggest they act primarily by 
antagonizing intracellular IFN-y signals. 
2. Materials and methods 
2.1. Cells, media, virus and reagents 
The experiments were done with the mouse macrophage cell line 
J774A.1 (ATCC TIB 67) grown in Dulbecco's modified Eagle's me-
dium with 5% fetal calf serum (Hyclone, LPS free) and antibiotics. 
Cultures of J774A.1 cells were infected with 3X 105 pfu/ml of the 
MS strain of HSV-2 prepared as previously described [27]. The murine 
recombinant cytokines were used at the following concentrations: 
IFN-y (Pharmingen), 100 IU/ml (10 ng/ml); TNF-a (Genzyme), 250 
U/ml (6.2 ng/ml); IL-4 (R&D Systems), 100 ng/ml; IL-13 (R&D sys-
tems), 100 ng/ml. Staurosporine (Sigma) was used at a concentration 
of 20 nM, which did not induce any overt toxicity in the cells. 
2.2. iNOS induction and assay of NO 
Cells (105/well; 6xl05/ml) were seeded in 96-well tissue culture 
plates (Nunc). The cells were left to settle for 2 h before stimulation 
and/or infection. Supernatants were harvested 24 h later and nitrite 
concentrations, as a correlate of NO production, were determined by 
use of the Griess assay as described earlier [26]. 
0014-5793/97/S17.00 © 1997 Federation of European Biochemical Societies. All rights reserved. 
P / /S0014-5793(97)00987-3 
62 S.R Paludan et al.lFEBS Letters 414 (1997) 61-64 
2.3. Western blotting of iNOS 
For analysis of iNOS protein levels, 2X106 cells were seeded in 35 
mm culture dishes (Nunc) at a concentration of 6X105 cells/ml and 
stimulated and/or infected 2 h later. After 24 h of treatment, cells were 
lysed (50 mM Tris-HCl, pH 7.5, 25 mM KC1, 5 mM MgCl2, 0.2% 
Triton-XlOO, 250 mM sucrose, protease inhibitors [28]) and cytoplas-
mic proteins harvested. Equal amounts of protein for each sample 
were subjected to SDS-PAGE and blotted onto a PVDF membrane 
(NOVEX). Western blotting was performed following the recommen-
dations of the antibody manufacturer (Transduction Laboratories) 
using a mouse monoclonal antibody against mouse iNOS (cat. no. 
N39120), a horse-radish peroxidase-conjugated goat anti-mouse anti-
body (cat. no. M15345) and DAB chromogen tablets (DAKO). 
2.4. iNOS mRNA detection by RT-PCR and Northern blot analysis 
From cells cultured and stimulated as for the Western blot analysis, 
total cellular RNA was extracted by the guanidinium thiocyanate 
procedure as described by Chomczynski and Sacchi [29]. RT-PCR 
was performed as described earlier [26] using Ohgo-(dT)i5 as primer 
for the RT and the following specific iNOS primers for the PCR: 
sense, 5'-CAC ATT CAG ATC CCG AAA CGC TTC TCT TC-3'; 
antisense, 5'-GAG CCT CGT GGC TTT GGG CTC CTC-3'. The 
amplified product spanned 1379 bp. 
For Northern blot analysis total RNA was poly(A)-selected using 
Ohgo-(dT)25 beads (Dynal), following the manufacturer's instructions. 
The mRNA was subjected to denaturing electrophoresis and trans-
ferred to a Zeta probe blotting membrane (Bio-Rad) and UV-cross-
linked. The hybridization and wash was done at 60°C using the buff-
ers recommended by Bio-Rad. As probe we used the 1379 bp PCR 
product mentioned above purified from a 1% low melting temperature 
agarose gel (NuSieve GTG Agarose, FMC) and labeled using the 
Random Primed DNA Labeling Kit from Boehringer-Mannheim. 
RNA loading of the gel was assessed by hybridization with a full-
length GAPDH-specific probe labeled as above. 
3. Results 
We have previously shown that IFN-y induces NO produc-
tion in mouse macrophages and that HSV-2 infection syner-
gistically enhances this production [26], To analyze the effect 
of possible down-regulators we tested the ability of the Th2 
cytokines IL-4 and IL-13 to antagonize this IFN-y- and HSV-
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Fig. 1. Effect of IL-4 and IL-13 on IFN-y-induced NO production 
in J774A.1 cells. The cells were treated with 100 IU/ml IFN-y, 100 
ng/ml IL-4, 100 ng/ml IL-13 and 100 U/ml TNF-a and infected 
with 3X105 pfu/ml of HSV-2 as indicated. After 24 h the amounts 
of nitrite in the supernatants were measured by the Griess assay. 
The results are expressed as mean ± S.E.M. of triplicate cultures. Es-
sentially similar results were obtained in two other experiments. 
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Fig. 2. Effect of IL-4 and IL-13 on iNOS protein levels in unin-
fected and virus-infected I774A.1 cells treated with IFN-y. The cells 
were treated with 100 IU/ml IFN-y, 100 ng/ml IL-4 and 100 ng/ml 
IL-13 and infected with 3x 105 pfu/ml of HSV-2 as indicated. After 
24 h the iNOS protein levels were assessed by Western blotting. 
nd = not done. 
2-induced activity in the murine macrophage cell line J774A. 1. 
As shown in Fig. 1 the IFN-y-induced NO production was 
totally abrogated by IL-4 and IL-13. Infection of the macro-
phages with HSV-2 did not in itself result in NO production 
(data not shown), but synergistically enhanced the IFN-y-in-
duced NO production. The synergistic enhancement was also 
reduced by IL-4 and IL-13, but the two cytokines were not 
able to eliminate NO production in virus-infected cells, even 
when a 10-fold higher dose of IL-4/IL-13 was used (data not 
shown). To investigate the mechanism employed by IL-4 and 
IL-13 to down-regulate NO production in murine macro-
phages, we replaced virus infection with TNF-a, which in 
an autocrine manner is responsible for the effect of the virus 
infection [26]. HSV-2 infection and TNF-a (250 U/ml) had the 
same effect on NO production, regardless what other stimuli 
were given (Fig. 1). This supports that HSV-2 works through 
TNF-a-induction and indicates that IL-4 and IL-13 can abol-
ish IFN-y-induced signal(s), but not counteract the TNF-a-
triggered signals, which are able to synergize with remaining 
IFN-y-induced signals. 
Having found that IL-4 and IL-13 down-regulate the ability 
of IFN-y to induce NO production, we decided to analyze at 
which stage of the induction pathway they work. Using West-
ern blotting we found that the iNOS protein levels correlated 
with the determined nitrite concentrations in both uninfected 
and virus-infected macrophages (Fig. 2a,b). Thus, IL-4 and 
IL-13 do not seem to modulate the activity of translated 
iNOS protein, but rather interfere with an earlier stage in 
NO production. 
By RT-PCR we showed that iNOS mRNA synthesis was 
completely shut down in IFN-y-stimulated cells treated with 
either IL-4 or IL-13 (Fig. 3a). In contrast, Northern blot 
analysis of virus-infected cells revealed that although the 
two Th2 cytokines were able to substantially reduce the 
amount of iNOS mRNA transcribed, they were not able to 
completely eliminate iNOS transcription when IFN-y-treated 
cells were infected with HSV-2 (Fig. 3b). From these results 
we conclude that IL-4 and IL-13 work by modulating the level 
of iNOS mRNA, whereas the activity of translated iNOS 
seems not to be affected. Furthermore, virus infection of the 
cells mediates signals, which can still cause iNOS transcription 
in spite of apparent extinction of the IFN-y signal by IL-4 or 
IL-13. 
It has been found that the broad-specificity kinase inhibitor 
staurosporine inhibits STAT6 phosphorylation [30]. Since 
STAT6 is known to be involved in many IL-4/IL-13-mediated 
S.R. Paludan et al.lFEBS Letters 414 (1997) 61-64 63 
IFN-7 
HSV-2 
IL-4 
IL-13 
-
nd 
-
-
+ 
nd 
-
-
+ 
nd 
+ 
-
nd 
iNOS iNOS 
GAPDil 
(a) (b) 
Fig. 3. Effect of IL-4 and IL-13 on iNOS mRNA levels in unin-
fected and virus-infected J774A.1 cells treated with IFN-y. The cells 
were treated with 100 IU/ml IFN-y, 100 ng/ml IL-4 and 100 ng/ml 
IL-13 and infected with 3 x10s pfu/ml of HSV-2 as indicated. After 
10 h the cells were lysed and total cellular RNA isolated. The pres-
ence of iNOS mRNA was assessed by (a) RT-PCR with iNOS-spe-
cific primers and (b) by Northern blot analysis of poly(A)-selected 
mRNA with an iNOS-speciflc probe. RNA loading of the gel for 
Northern blot analysis was assessed by hybridization with a 
GAPDH-specific probe. 
functions, we tested if staurosporine was able to influence the 
ability of IL-4 and IL-13 to down-regulate IFN-y-induced NO 
production. As shown in Fig. 4, staurosporine abolished the 
ability of IL-4 and IL-13 to counteract IFN-y both in the 
presence and absence of HSV-2 infection. Furthermore, it is 
seen that the synergistic effect of HSV-2 on IFN-y-induced 
NO production is also abolished upon staurosporine treat-
ment. 
4. Discussion 
In the present study we have analyzed the effect and mech-
anism of action of the Th2-cytokines IL-4 and IL-13 on the 
production of NO in a murine macrophage cell line stimulated 
with IFN-y and the influence of infection with HSV-2 on this 
process. A prominent activity described for both IL-4 and IL-
13 is to counteract IFN-y-induced activities [17,18,20]. Among 
these, down-regulation of iNOS, which catalyzes the produc-
tion of NO from arginine, has been reported [28]. 
We have previously shown that infection of murine perito-
neal macrophages with HSV-2 synergistically enhances IFN-y-
induced production of NO, mainly or exclusively through 
autocrine secretion of TNF-a [26]. Our present data show 
that IL-4 and IL-13 totally abrogate IFN-y-induced NO pro-
duction, but only partially suppress NO production during 
HSV-2 infection or after treatment with TNF-a. These results 
indicate that IL-4 and IL-13 work primarily by antagonizing a 
step in the IFN-y signal downstream of the IFN-y receptor, 
and that signals induced by virus infection (or exogenously 
added TNF-a) are not or to a lesser extent affected by IL-4 
and IL-13. These signals, which by themselves a not able to 
induce production of NO, exert a synergistic effect on the 
otherwise down-regulated IFN-y signal and induce some 
iNOS transcription and NO production in spite of high con-
trations of IL-4 or IL-13. 
It is known that the transcription factors IRF-1 and ST ATI 
are essential for the transcription of the iNOS gene and many 
other IFN-y-induced genes [31,32]. IRF-1 is itself induced by 
STAT1 [33]. This, together with our finding that IL-4 and IL-
13 down-regulate iNOS at the mRNA level, suggest two pos-
sible mechanisms by which the two Th2 cytokines might coun-
teract IFN-y: (1) inhibition of the Janus kinase (Jak)/STAT 
pathway, possibly through activation of a phosphatase that 
dephosphorylates the IFN-y receptor, Jakl, Jak2 or STAT1; 
(2) inhibition of IRF-1 activity, mediated by IL-4-induced 
factor(s) transcribed via a staurosporine sensitive mechanism. 
In this context it is interesting that IL-4 and IL-13 are unable 
to down-regulate IFN-y-induction of iNOS in STAT6-defi-
cient mice [34] and that STAT6 phosphorylation is inhibited 
by staurosporine [30]. This could point to STAT6 as being 
involved in the above process. Another possible mechanism 
also exists, namely that IL-4 and IL-13 destabilize iNOS 
mRNA. However, this has been tested by Bogdan et al. for 
IL-4 [28] and found not to be the case. For IL-13, this has not 
been explored yet but is a subject of future investigations. 
The observation that IFN-y after HSV-2 infection or after 
addition of TNF-a is able to induce some iNOS activity de-
spite the presence of IL-4 or IL-13 might be due to activation 
of N F - K B . TNF-a induces translocation of N F - K B to the 
nucleus [35] and the iNOS promoter contains two N F - K B sites 
[36]. It therefore seems plausible that HSV-2 infection via 
TNF-a secretion activates N F - K B , which in turn induces 
some degree of iNOS transcription in the presence of IFN-
y-activated factors and that IL-4 and IL-13 do not work at 
this level. That the synergistic enhancement of IFN-y-induced 
NO production by HSV-2 is mainly due to N F - K B activation 
is indicated by our data, showing that staurosporine abolishes 
the synergistic effect of HSV-2 infection on NO production, 
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Fig. 4. Effect of staurosporine on the ability of IL-4 and IL-13 to 
down-regulate IFN-y-induced NO production in J774A.1 cells. The 
cells were treated with 100 IU/ml IFN-y, 100 ng/ml IL-4, 100 ng/ml 
IL-13 and 20 nM staurosporine (Stau) and infected with 5X105 
pfu/ml of HSV-2 as indicated. After 24 h the amounts of nitrite in 
the supernatants were measured. The results are expressed as 
mean ± S.E.M. of triplicate cultures. Essentially similar results were 
obtained in another two experiments. 
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and by the fact that staurosporine is known to inhibit I - K B 
phosphorylation, thus hindering N F - K B activation [37]. 
Taken together, our results show that the Th2 cytokines IL-
4 and IL-13 completely abrogate the induction of iNOS by the 
T h l cytokine IFN-y and that virus infection of the cells, pos-
sibly through autocrine T N F - a secretion, exerts a signal 
which partially compensates for the action of the Th2 cyto-
kines. The level of action of IL-4/IL-13 is prior to iNOS t ran-
scription. We are currently studying in more details the mo-
lecular mechanisms underlying the down-regulation, which 
might give a clue to the immunologically central dichotomy 
of the relationship between IL-4/IL-13 and IFN-y. In the con-
text of a virus infection our findings suggest a mechanism 
whereby the body might down-regulate a harmful systemic 
N O production while allowing a sustained product ion of 
this potential antiviral principle in infectious foci. 
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